

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Spasmomen 40 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Spasmomen film-coated tablet contains 40 mg of otilonium bromide (*otilonii bromidum*).

Excipient with known effect: lactose hydrate (28.0 mg)

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablets.

White to almost-white round shaped, biconvex film-coated tablets.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Symptomatic treatment of irritable bowel syndrome (IBS) and painful, spastic states of distal parts of the intestinal tract (colon and rectum), for relief of abdominal pain, distension and motility disorders in patients older than 18 years old, caused by smooth muscle spasm of distal parts of the intestinal tract.

Pharmacological treatment of irritable bowel syndrome should be started with previously introduced non-pharmacological measures (change of life style, diet, emotional support, psychotherapy) if they did not bring the wanted therapeutic effect on their own.

4.2 Posology and method of administration

Posology

Recommended single dose is one 40 mg tablet, recommended daily dose is 80-120 mg (1 tablet 2 to 3 times daily). Dosage is prescribed depending on the clinical picture and response to treatment, and in accordance with therapeutic guidelines for the treatment of irritable bowel syndrome.

Duration of treatment: there is no limitation, it depends on the disease course. Physicians should periodically assess the need for continued treatment.

Special populations

Patients with hepatic or renal impairment

Dose adjustment is not necessary (see section 5.2).

Elderly

Dose adjustment is not necessary.

Paediatric population

The safety and efficacy of otilonium bromide in patients below 18 years have not been established, therefore this medicinal product is not recommended for use in this population.

Method of administration

Tablets should be swallowed whole, with a glass of water, preferably 20 minutes before meal.

4.3 Contraindications

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Caution is needed when used in patients with glaucoma, prostatic hypertrophy and pyloric stenosis.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

4.5 Interaction with other medications and other forms of interaction

No interaction studies of otilonium bromide with other products were performed. It seems that the effect of otilonium bromide on total time of gastrointestinal transit, at the recommended dose of 40 mg 2 or 3 times daily, is not relevant for the absorption of other, orally taken concomitant medicinal products.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no clinical data about the use of otilonium bromide in pregnant women. Animal studies did not show embryotoxic, teratogenic or mutagenic effects or reproductive or developmental toxicity (see section 5.3).

Breast-feeding

There are no clinical data on the use of otilonium bromide in lactating women.

As a precautionary measure, it is preferable to avoid the use of Spasmomen during pregnancy and breast-feeding. Spasmomen should only be given to pregnant women and nursing mothers only if absolutely necessary and under close medical supervision.

Fertility

There are no data on the effect of otilonium bromide on human fertility. No effects on fertility have been observed in animal studies with female and male rats.

4.7 Effects on ability to drive and use machines

Spasmomen has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

In the clinical trial conducted with otilonium bromide the drug was well tolerated, the reported adverse events are very few in number and superimposable to those reported in placebo/reference drug groups (see table below)

Tabulated list of adverse reactions collected during clinical trials

The frequency of adverse reactions occurring in patients treated with otilonium bromide is classified as follows: Common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$) and rare ($\geq 1/10,000$ to $< 1/1,000$)

Gastrointestinal disorders	Uncommon: Dry mouth Nausea Abdominal pain upper
Skin and subcutaneous tissue disorders	Uncommon: Pruritus Erythema
General disorders and administration site conditions	Uncommon: Fatigue Asthenia
Nervous system disorders	Uncommon: Headache
Ear and labyrinth disorders	Uncommon: vertigo

During postmarketing surveillance, isolated reports on skin hypersensitivity reactions (urticaria, angioedema) have been received. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which, therefore, is not known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via national reporting system.

4.9 Overdose

Otilonium bromide was proven practically devoid of toxicity in animals, used in doses that exceeded many times the usual pharmacological dose (please see section 5.3). Therefore, also in man, no symptoms of overdose are expected. In case of overdose an appropriate symptomatic and supporting therapy is recommended.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Synthetic anticholinergic agents, quaternary ammonium compounds, ATC code: A03AB06

Otilonium bromide is the prototype of a class of 2-aminoethyl-N-benzoylamino-benzoate quaternary salts.

Pharmacodynamic effects

Otilonium bromide possesses an antispastic action on the smooth muscle of the distal part of the intestine (colon and rectum).

It shows this effect at doses that do not affect gastric secretion or produce typical atropine-like adverse effects.

Mechanism of action

Otilonium bromide acts predominantly by modifying Ca(2+) fluxes from cellular and extracellular sites and therefore reduces the trigger of contractile activity. It inhibits Ca(2+) entry into intestinal smooth muscle cells through L-type Ca(2+) channels and receptor (tachykinin and muscarinic)-induced opening of these channels.

Clinical efficacy and safety

An extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide, conducted in 378 IBS patients (SpC1M study) showed that the rate of response to treatment within 2–4 months was significantly higher in the otilonium bromide group (36.9%) than in the placebo group (22.5%; $P=0.007$). In each month of treatment, the rate of monthly response was higher in the otilonium bromide group as compared to the placebo group ($P < 0.05$). The total monthly and weekly responses to the single endpoints (intensity and frequency of pain and discomfort, meteorism/abdominal distension, severity of diarrhoea or constipation and mucus in the stool) were significantly more frequent in the group treated with otilonium bromide than in the placebo-treated group, with differences ranging from 10% to 20%. The subgroup analysis of the intestinal habits endpoint indicates that patients with diarrhoea have an additional benefit. Safety findings were superimposable to those of placebo.

Otilonium bromide has been confirmed effective in a recent double-blind, placebo-controlled large ($n=356$ IBS patients) clinical trial (OBIS study) confirming its superiority to placebo in reducing the frequency of abdominal pain, severity of abdominal bloating and prevention from symptom relapse.

5.2 Pharmacokinetic properties

Absorption

Otilonium bromide comes to the site of pharmacological effect probably directly through the intestinal wall, because the systemic absorption of the drug after oral administration is very low (3%). Therefore, its plasma concentration is low.

Distribution

After oral use, high distribution of the drug in the smooth muscles of the colon and rectum has been described. Drug used shortly before the meal ensures pharmacologically effective local bioavailability of the product, on the site of therapeutic action and in time of the expected most prominent symptoms of the disease.

Renal and hepatic impairment

Otilonium bromide is not studied in patients with impaired renal and hepatic function. Since orally used otilonium bromide is very scarcely absorbed in systemic circulation, the effect of reduced hepatic and renal function on its local exposition is not expected.

5.3 Preclinical safety data

Acute toxicity: no fatal cases were reported at oral doses of up to 1000 mg/kg in dogs, DL₅₀ of orally used otilonium bromide in rats is 1500 mg/kg.

Chronic toxicity: animal studies showed no haematological or histological abnormalities at otilonium bromide doses of 80 mg/kg for 180 days.

Embriotoxicity: no embryotoxic and teratogenic effects were observed in rats and rabbits at doses of up to 60 mg/kg.

Genotoxicity: standard in vitro and in vivo non clinical tests have not shown any mutagenic potential of otilonium bromide.

Environmental Risk Assessment

Environmental risk assessment studies have shown that otilonium bromide may pose a risk for soils (see section 6.6 for a correct disposal).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

rice starch
lactose hydrate
sodium starch glycolate
magnesium stearate

Film coat:

hypromellose
titanium dioxide (E 171)
macrogol 4000
macrogol 6000
talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Store at room temperature and protect from direct sun light.

6.5 Nature and contents of container

Each carton contains 30 film-coated tablets in blisters (PVC/PVdC/Al blister).

6.6 Special precautions for disposal and other handling

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

A. Menarini Industrie Farmaceutiche Riunite Srl, Via Sette Santi 3, 50131 Florence.

8. MARKETING AUTHORISATION NUMBER

BERLIN/GER/0001

9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17 June 2016

Date of latest renewal: 06 August 2020

10. DATE OF REVISION OF THE TEXT

15/02/2022